AstraZeneca Planning Faslodex NDA For First Quarter; Agent First In Class
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
AstraZeneca is predicting a first quarter 2001 NDA filing for its advanced breast cancer drug Faslodex (ICI 182780). The submission will be based on studies in post-menopausal women whose cancer progressed or recurred on tamoxifen or other endocrine therapies.